A phase I dose-escalation study of SYHA1813, a VEGFR and CSF1R inhibitor, in patients with recurrent High-Grade Gliomas or Advanced Solid Tumors.

导出 OA

翻译打印收藏纠错

第一作者： Zhuang,Kang

第一单位： Department of Neuro-Oncology, Cancer Center, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.

作者： Zhuang,Kang ^[1] ; Shenglan,Li ^[1] ; Yi,Lin ^[1] ; Yongsheng,Li ^[2] ; Ying,Mao ^[3] ; Jing,Zhang ^[4] ; Ting,Lei ^[5] ; Haidan,Wang ^[6] ; Yangzhi,Su ^[6] ; Yang,Yang ^[6] ; Jingbo,Qiu ^[6] ; Wenbin,Li ^[7]

作者单位： Department of Neuro-Oncology, Cancer Center, Beijing Tiantan Hospital, Capital Medical University, Beijing, China. ^[1] Department of Medical Oncology, Chongqing University Cancer Hospital, Chongqing University, Chongqing, China. ^[2] Department of Neurosurgery, Huashan Hospital, Fudan University, Shanghai, China. ^[3] Phase I Clinical Research Center, Huashan Hospital, Fudan University, Shanghai, China. ^[4] Department of Neurosurgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology, Wuhan, China. ^[5] Department of Clinical Development, CSPC Pharmaceutical Group Limited, Shijiazhuang, China. ^[6] Department of Neuro-Oncology, Cancer Center, Beijing Tiantan Hospital, Capital Medical University, Beijing, China. liwenbin@ccmu.edu.cn. ^[7]

关键词 CSF1R Dose escalation High-grade glioma Phase I Solid tumor VEGFR